Description
RGDS is a tetrapeptide that delivers attached compounds to targets such as thrombus or tumor cells; it enhances efficacy of anticancer and anti-aggregation or anti-adhesion compounds. RDGS binds integrins on the surfaces of cells. RGDS also exhibits anti-inflammatory benefit, improving ventilation-induced lung injury by preventing activation of NF-κB and suppressing production of TNF-α and IL-6 in vivo.
References
Inoue T, Hashimoto R, Matsumoto A, et al. In vivo Analysis of Arg-Gly-Asp Sequence/Integrin α5β1-Mediated Signal Involvement in Embryonic Enchondral Ossification by exo utero Development System. J Bone Miner Res. 2013 Dec 27. [Epub ahead of print]. PMID: 24375788.
Wang B, Wan JY, Zhang L, et al. Synthetic RGDS peptide attenuates mechanical ventilation-induced lung injury in rats. Exp Lung Res. 2012 May;38(4):204-10. PMID: 22452721.
Zhao M, Wang C, Jiang X, et al. Synthesis of RGD containing peptides and their bioactivities. Prep Biochem Biotechnol. 2002 Nov;32(4):363-80. PMID: 12455829.
Preferred conformations of RGDX tetrapeptides to inhibit the binding of fibrinogen to platelets.
Park HS, Kim C, Kang YK. Biopolymers. 2002 Apr 15;63(5):298-313. PMID: 11877740.